- National Primary Health Care Development Agency (NPHCDA) announced the commencement of malaria vaccine rollout in Kebbi and Bayelsa states on December 2, 2024
- The first phase is to target children between 5 and 15 months old, with plans to expand the program across Nigeria
- Kebbi aimed to vaccinate 595,000 children in the first phase, with the next phases planned for 2025
The National Primary Health Care Development Agency (NPHCDA) has announced that the first phase of the malaria vaccine rollout in Nigeria begins on Monday, December 2, 2024.
The vaccination campaign will initially focus on Kebbi and Bayelsa states.
The announcement was made on Saturday, November 30, by Remi Adeleke, Head of the Public Relations Unit at NPHCDA, and Professor Olugbenga Mokuolu, Strategic Advisor to the Coordinating Minister of Health and Social Welfare. The initiative marks a significant step in the country’s efforts to combat malaria, a leading cause of morbidity and mortality in Nigeria.
Nigeria's malaria vaccine rollout starts in Bayelsa, Kebbi
“Malaria vaccination commences on December 2nd, 2024 in Bayelsa, and Kebbi states,” Adeleke stated.
Recall that the federal government received a one-million-dose shipment of the R21/Matrix-M malaria vaccine in October, courtesy of Gavi, the Vaccine Alliance. UNICEF and the World Health Organisation (WHO) supported the delivery.
Dr. Muyi Aina, Executive Director of NPHCDA, stated that the vaccine will be given to children between the ages of five months and 15 months as part of the regular immunisation schedule.
“The introduction will be expanded to other states and integrated into our national routine immunisation schedule, as we receive additional doses.
“The second phase will target 19 states and FCT, while the third phase will target the remaining 15 States. Both phases are scheduled for 2025,” Aina stated.
Junaidu Haliru Gwandu, Director of Immunisation and Disease Control at Kebbi State Primary Healthcare Development Agency, said the state’s goal is to vaccinate 595,000 children in the first phase of the malaria vaccine rollout.
The WHO representative in Nigeria, Dr. Walter Mulombo said, “We are confident that this vaccine, in combination with other preventive measures, will drastically reduce the burden of malaria in Nigeria and help us move closer to achieving the goal of a malaria-free Africa.”
Malaria is one of the leading causes of death in Nigeria and across Africa, claiming the lives of hundreds of thousands of children under five annually. Nigeria bears approximately 27% of the world’s malaria cases and 31% of global malaria-related deaths.
The R21 malaria vaccine, developed by Oxford University and produced by the Serum Institute of India and Novavax, is one of the first to receive support from Nigeria. It is specifically aimed at preventing malaria in children and is not intended for adults.
Good news for sickle cell patients as LUTH launches bone marrow transplant treatment
Meanwhile, TheRadar earlier reported that the Lagos University Teaching Hospital (LUTH) and Sickle Cell Foundation Nigeria (SCFN) announced a bone marrow transplant program for sickle cell disease.
Comprehensive care included newborn screening and chronic blood transfusion therapy.
